Pharmaceutical Products / Drugs Technology Offers

By Type

Yissum - Research Development Company of the Hebrew University posted this:

New CNS-Active Carbamate Derivatives for Epilepsy New CNS-active carbamate derivatives of branched aliphatic carboxylic acids with 4-aminobenzensulfonamide with a broad potent antiepileptic activity Project ID : 6-2017-4419

New CNS-Active Carbamate Derivatives for Epilepsy

Eva Gabaldon posted this:
Licensing Manager at Spanish National Research Council

Efavirenz use for Niemann-Pick C treatment CSIC has developed and brought to preclinical stage a novel non-invasive pharmacological treatment for Niemann Pick disease Type C (NPC) and other lysosomal storage disorders where cholesterol accumulates in the brain.

Efavirenz use for Niemann-Pick C treatment

Maria João Cardoso posted this:
Science and Technology Manager at UATEC - Unidade de Transferência de Tecnologia

Magnetic nanoparticles for selective enrichment of proteins in complex mixtures New method for preparing ion chelating magnetic nanoparticles, which allow selective protein enrichment, namely metalloproteases (MMPs) and His-tagged proteins, from complex mixtures.

Magnetic nanoparticles for selective enrichment of proteins in complex mixtures

Universidad de Alcalá-OTRI posted this:

Compounds for the treatment of Leishmania infections The research group Heterobetainas of the University of Alcalá presents the preparation and uses of a series of compounds that act as bioactive agents against the Leishmania parasite and as therapeutic agents in the treatment of this disease, in both, its visceral (LV) version and in the mucocutaneous one (CML). The group is looking for pharmaceutical companies interested in manufacturing an active ingredient for the formulation of a leishmanicidal drug based on these compounds. The group proposes the signing of a patent license agreement, a collaboration agreement or a commercial agreement with technical

Compounds for the treatment of Leishmania infections

Núria Brunet i Garcia posted this:
Licensing Manager at Universitat de Lleida

New therapeutic candidate for Spinal Muscular Atrophy We are looking for a licensing agreement with a company with expertise in the field of neurosciences. More particularly, we are willing to find a company involved in the development of therapeutic solutions for the rare disease Spinal Muscular Atrophy (SMA).

Maria João Cardoso posted this:
Science and Technology Manager at UATEC - Unidade de Transferência de Tecnologia

Innovative methodology for nanoencapsulation of montelukast in cyclodextrin Cyclodextrin is a nano-sized capsule that allows increasing the stability and aqueous solubility of active pharmaceutical ingredients such as montelukast. This technology comprehends an alternative method to obtain an amorphous solid composed by montelukast and cyclodextrin. In alternative to conventional methodologies, this method allows the encapsulation to occur without requiring the use of solvents and the formation of degradation products.

Innovative methodology for nanoencapsulation of montelukast in cyclodextrin

Universidad de Granada posted this:

Method for isolating circulating epithelial pulmonary cells and their use as markers for diagnosing Chronic Obstructive Pulmonary Disease (COPD)A procedure is described based on Liquid Biopsy techniques that allows both the diagnosis of COPD, as well as its evolution in patients. In order to do that, circulating pulmonary cells (CPCs) that could be present in blood of patients diagnosed with COPD are detected and characterized by combining two different techniques: - Immunogenetic positive selection for their isolation in peripheral blood. - Immunocytochemistry for detecting CPCs by using specific markers for pulmonary epithelial cells.

Method for isolating circulating epithelial pulmonary cells and their use as markers for diagnosing Chronic Obstructive Pulmonary Disease (COPD)

Russell Nicholls posted this:
Licensing Manager at Curtin University

Rhenium compounds as anticancer agents Metal-based anticancer agents, such as cisplatin, are used as gold standard cancer therapies. While these drugs are effective in eradicating malignant cells, their selectivity is poor, meaning that significant adverse effects are experienced during treatment through damage inflicted on healthy cells. Improved selectivity and targeted cancer therapies with minimal side effects are being sought. Many drugs have been developed which contain platinum, and other metals are now being developed as anticancer agents. Researchers at Curtin University developed a series of rhenium containing compounds that target cancerous cells and block their growth. These compounds are promising candidates for treatment of tumours with aggressive potential for metastasis (for example, pancreatic cancer). A library of molecular candidates have been synthesized, and structure-activity relationship to modulate selectivity and therapeutic potential has been explored.

Universidad de Alcalá-OTRI posted this:

Derivatives of Indolin-2-one and its therapeutic use in inflammatory, autoimmune, metabolic, cardiovascular, neurological and cancer diseases.The research group of “Neuroendocrinology of the cannabinoid / vanilloid system” of the University of Alcalá, in collaboration with researchers from the Institute of Medical Chemistry of CSIC, have developed a series of compounds derived from indolin-2-one, emphasizing the pharmaceutical compositions containing in the compounds and their use for the treatment of diseases mediated by AMPK (AMP-activated kinase), particularly inflammatory, autoimmune, metabolic, cardiovascular, neurological and cancer. The group is looking for companies in the pharmaceutical and health sector with the objective of reaching technical cooperation agreements, commercial agreements with technical assistance or patent licensing.

Derivatives of Indolin-2-one and its therapeutic use in inflammatory, autoimmune, metabolic, cardiovascular, neurological and cancer diseases.

Mª Eugenia Garcés Castellote posted this:
Commercialization Specialist at Universidad de Alcalá-OTRI

New inhibitor compounds of the tyrosine phosphatase 1B protein The research group in "Biological Chemistry" of the University of Alcalá has developed new compounds inhibitors of the Tyrosine Phosphatase 1B Protein, which are related to new Formulas I, II and III, with methods to prepare them, with the use of them as inhibitors of protein tyrosine phosphatase 1B (PTP1B) and with the use of the intermediates that lead to that compounds to prepare an inhibitor of PTP1B comprised by that formulas. These compounds have application in the treatment or prevention of diseases in which it is known that PTP1B is involved in the pathogenesis, so they can be used for the treatment of insulin resistance, glucose intolerance, obesity, diabetes mellitus, hypertension and ischemic diseases of large and small blood vessels, conditions that accompany type 2 diabetes and other disorders where insulin resistance is indicated. The group looks for companies in the health and pharmaceutical sector with the aim of reaching technical collaboration agreements, commercial agreements or patent licenses agreements.

New inhibitor compounds of the tyrosine phosphatase 1B protein

Universidad de Alcalá-OTRI posted this:

Carbosilane dendrons functionalized with fatty acids: Formation of micelles and uses in biomedicine as antiviral, antibacterial, antiprionic, antimicrobial and drug transporters.The research group of the University of Alcalá in «Dendrimers for biomedical applications» presents the following invention that refers to the formation of dendrons of carbosilane structure that have in their periphery preferably anionic or cationic groups and in the focal point fatty acids or derivatives of these. Its main field of application is in biomedicine, as non-viral transport agents, as drug transporters, to elaborate a drug, as antimicrobial, antiviral or antipyretic agents. In the environmental sector we also find its application as biocides for water treatment. The group seeks to reach license agreements, collaboration or commercial agreements with technical assistance with companies from the sector of Health, Pharma and Environment.

Universidad de Alcalá-OTRI posted this:

Carbosilane dendrimers with terminal thiol groups on their surface. Their preparation and their uses.The research group in «Dendrimers for biomedical applications» of the University of Alcalá presents the procedure for obtaining and using carbosilane dendrimers with terminal thiol groups on their surface, as antioxidants and radical scavengers for their application in the food industry, cosmetic and pharmaceutical. The group seeks to reach licensing agreements, collaboration agreements or commercial agreements with technical assistance, with enterprises from the food industry, cosmetic, biotechnology, Biomedicine or pharmaceutical sector.

Carbosilane dendrimers with terminal thiol groups on their surface. Their preparation and their uses.

UNIVERSIDAD DE ALICANTE posted this:

Holographic sensor for detection of adulterants in essential oils The research group of Holography and Optical Processing of the University of Alicante has developed a holographic technique for the detection of adulterants in essential oils. This technique is able to detect different types of adulterants qualitatively. In addition, a quantitative measurement of the degree of adulteration of an essential oil can also be performed by means of pre-calibration of the sensor for a particular adulterant. The sensor could be miniaturized and manufactured at a low cost compared to traditional methods of analysis such as gas chromatography and high performance liquid chromatography. The sensor can be used by unqualified personnel.

Holographic sensor for detection of adulterants in essential oils

Mind the Byte posted this:

SaaS Platform for Drug Discovery Our SaaS platform has been developed by Mind the Byte to break through the most important technological and economic barriers of computational design for companies and research centres.

SaaS Platform for Drug Discovery

Zepponi Vanessa posted this:
Business Developer at CVT Valorisation Sud

Vaccine against bubonic and pneumonic plague Our offer is a vaccine against Bubonic and Pulmonary Plague. It was developed by researcher from the Pasteur Institute of Paris who is a WHO collaborating center on Plague.

1
2
3
4
5